|Day Low/High||1.15 / 1.26|
|52 Wk Low/High||0.92 / 2.50|
New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.
Expanding use of Abraxane into pancreatic cancer could net Celgene another $1 billion in revenue.
Celgene's Abraxane delays tumor growth in patients with advanced melanoma.
A study of Abraxane in pancreatic cancer generates a ton of buzz even with data still weeks away.
How best to invest in the next important clinical trial catalyst facing Celgene.